Reach Us +1-217-403-9671
Average, Individual And Population Bioequivalence - Understanding The True Variability Of A Product | 8351
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Average, individual and population bioequivalence - understanding the true variability of a product

International Conference & Exhibition Bioequivalence and Bioavailability

Bhaswat S. Chakraborty

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.1000001

E stablishment of bioequivalence has generally been relied on the comparison of estimated population averages of rate (C max ) and extent of absorption (AUC) of drug from different pharmaceutical equivalents. The concepts of individual bioequivalence (IBE), introduced in 1990s for drug switchability and population bioequivalence (PBE) for drug prescribability assessed through limited sequence, four period, replicate, crossover design made possible estimation of not only inter- subject variation but also intra-subject variability due to subject-by- formulation interaction. More interestingly, such designs often provide a more accurate and reliable assessment of Average Bioequivalence (ABE) than that obtained from traditional 2-period crossover studies. An analysis of relative merits and demerits of ABE, IBE and PBE will be carried out in the presentation. Application of mixed effect models for analysis of replicate studies and understanding the variabilities will be discussed. A case study of a semi-simulated, replicate, crossover study of alverine citrate 120 mg capsules in 48 healthy volunteers will also be presented. In this study, two formulations of alverine were found to be average bioequivalent as 90 % CI for AUC and C max were entirely within 80-125%. Very interestingly, population and individual bioequivalence were also demonstrated for these formulations as the upper bound of 90% CI, as calculated by a mixed effect ANOVA model, was a negative value. However, one has to be careful as the results obtained from different softwares (e.g., MS Excel, SAS and WinNonlin) can be different owing to model optimization and treatment of missing data
Relevant Topics